Herein, we analyzed arguably the largest cohorts to assess the efficacy of crizotinib and pemetrexed-based regimen in Chinese NSCLC patients with ROS1 rearrangement in this study. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.